Carlsbad, CA, Nov. 07, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a biopharmaceutical company focused on developing and advancing novel therapeutics for ...

Thomas Bieber, University of Bonn, Germany, wasted no time in welcoming his colleagues from around the world to the ...

Third quarter net product revenues for ZORYVE® (roflumilast) franchise of $44.8M, with $22.0M for ZORYVE cream 0.3%, $20.3M for ZORYVE topical ...

Crucially, it extends the label for the PDE 4 inhibitor to include people with mild psoriasis, unlocking a sizeable new market for the drug, which has been approved since 2014 for moderate to ...

fuelled by head-to-head studies showing it was more effective at treating moderate-to-severe psoriasis than Amgen's drug, which acts as a PDE4 inhibitor. Results from the POETYK PSO-1 and POETYK ...

ZORYVE cream - a highly potent and selective phosphodiesterase-4 (PDE4) inhibitor ... Janus kinase type 1 (JAK1) inhibitor, designed to preferentially deliver the drug deep into the hair follicle ...

PALI-2108 is an orally administered, locally acting colon-specific PDE4 inhibitor prodrug in development for patients ... PALI-2108, and higher drug manufacturing costs, were offset by a decrease in ...

This orally administered, colon-specific phosphodiesterase-4 (PDE4) inhibitor prodrug is in development for patients with ulcerative colitis (UC). The poster titled “Colonic Bioactivation and ...

Over the last few years, the SARS-CoV-2 virus, responsible for COVID-19, has undergone significant changes, evolving from the ...

Scientists from Duke-NUS Medical School and their collaborators have identified an inherited genetic variation prevalent ...

Moreover, the approval of several ROS1 inhibitors by regulatory bodies like the Food and Drug Administration (FDA) and European Medicines Agency (EMA) has further fueled market growth, providing ...

The ROS-1 NSCLC current market is mainly dominated by tyrosine kinase inhibitors such as XALKORI at present and is anticipated to be dominated by Repotrectinib, Taletrectinib, and NVL-520 by 2034.